Abstract:Arsenic compounds, including arsenic trioxide (As2O3) and arsenic sulfide (As4S4), have recently been shown to be effective in the treatment of acute promyelocytic leukemia (APL). In vitro, As2O3 exerts a dosedependent dual effect: it triggers apoptosis at relatively high concentrations (0.5 to 2.0 μmol/L) and induces partial differentiation at low concentrations (0.1 to 0.5 μmmol/L). The apoptosis-inducing effect is associated with the collapse of mitochondrial transmembrane potentials in a thiol-dependent manner, whereas the retinoic acid signaling is required for APL cell differentiation. As2O3 over a wide range of concentrations (0.1 to 2.0 μmol/L) induces degradation of PML-RARα as well as the wild-type PML and enhances the acetylation of histone, a process important for the transcriptional activation of genes. In vivo, As2O3 induces a high complete remission (CR) rate in patients with both primary and relapsed APL (around 85% to 90%). Side effects, such as skin reaction, gastrointestinal symptoms, electrocardiographic (EKG) changes, neuropathy, and liver dysfunction, are mild to moderate in relapsed patients, and severe hepatic lesions have been found in some primary cases. After CR obtained in relapsed patients, chemotherapy in combination with As2O3 as postremission therapy has yielded better survival than treatment with As2O3 alone. This is in line with the observation that remission induction with As2O3 is not sufficient in most cases to obtain a molecular remission as judged by reverse-transcriptase polymerase chain reaction for PML-RARα fusion transcripts. The in vivo effect of As2O3 seems to be related to the expression of APL-specific PML-RARα oncoprotein, and a synergistic effect between As2O3 and ATRA has been shown in the APL mouse model. Besides As2O3, other arsenic compounds such as As4S4 also show a therapeutic effect in APL. Because the toxic effects of arsenic treatment in primary APL need to be investigated further, we propose use of ATRA as a first-line drug for remission induction in primary APL, whereas As2O3 can be incorporated into multidrug postremission therapy or used as rescue for relapsed APL patients.

Role of Myc in Differentiation and Apoptosis in HL60 Cells after Exposure to Arsenic Trioxide or All-Trans Retinoic Acid

Treatment of Acute Promyelocytic Leukemia with ATRA and As2O3: a Model of Molecular Target-Based Cancer Therapy.

A Model of Molecular Target-Based Cancer Therapy

Arsenic-induced PML Targeting Onto Nuclear Bodies: Implications for the Treatment of Acute Promyelocytic Leukemia

Arsenic Trioxide-Induced Apoptosis and Differentiation Are Associated Respectively with Mitochondrial Transmembrane Potential Collapse and Retinoic Acid Signaling Pathways in Acute Promyelocytic Leukemia

Arsenic trioxide, a therapeutic agent for APL.

Mutations of Epigenetic Modifier Genes As A Poor Prognostic Factor in Acute Promyelocytic Leukemia under Treatment with All-Trans Retinoic Acid and Arsenic Trioxide

Synergic Effects of Arsenic Trioxide and Camp During Acute Promyelocytic Leukemia Cell Maturation Subtends a Novel Signaling Cross-Talk

Varying Responses of PML-RARA with Different Genetic Mutations to Arsenic Trioxide.

Treatment of Acute Promyelocytic Leukemia with Arsenic Compounds: in Vitro and in Vivo Studies

All -trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells

Arsenic Trioxide-Induced Mitotic Arrest and Apoptosis in Acute Promyelocytic Leukemia Cells

Pathways of retinoic acid- or arsenic trioxide-induced PML/RARα catabolism, role of oncogene degradation in disease remission

Synergistic action of all-trans retinoic acid and arsenic in the treatment of acute promyelocytic leukaemialeukemia on transcriptional expression and epigenetic regulation

In Vitro Studies on Cellular and Molecular Mechanisms of Arsenic Trioxide (as2o3) in the Treatment of Acute Promyelocytic Leukemia: As2O3 Induces NB4 Cell Apoptosis with Downregulation of Bcl-2 Expression and Modulation of PML-RAR Alpha/pml Proteins

Efficacy and resistance of molecularly targeted therapy for myeloid malignancies Mechanisms of action and resistance to all-trans retinoic acid ( ATRA ) and arsenic trioxide ( As 2 O 3 ) in acute promyelocytic leukemia

Acute Promyelocytic Leukemia, Retinoic Acid, and Arsenic: A Tale of Dualities

[Involvement of PML Proteins in Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide].

PML Gene,arsenic and Apoptosis of Leukemic Cells

Curing APL through PML/RARA degradation by As2O3.

[Experimental study of low dose arsenic trioxide in treatment of patients with acute promyelocytic leukemia].